Arrowhead Research Inks Deal With Alnylam

Pasadena-based Arrowhead Research and RNAi therapeutics firm Alnylam Pharmaceuticals announced this morning that the two are in a collaboration and licensing agreement. Financial details of the agreement were not announced. THe two said that Arrowhead will receive a license from Alnylam to develop a RNAi therapeutic aimed at the Hepatitis B Virus (HBV). The companies said the license enables the discovery, development, and commercialization of an RNAi therapeutic targeting the hepatitis B virus (HBV) by Arrowhead, with Alnylam receiving milestone payments and royalties on sales of products derived from that license. Arrow head will also be providing its Dynamic Polyconjugate (DPC) delivery technology to Alnylam, for similar milestone and royalty terms


More Headlines